Nitric Oxide-Dependent Reduction in Soluble Guanylate Cyclase Functionality Accounts for Early Lipopolysaccharide-Induced Changes in Vascular Reactivity
Open Access
- 1 March 2006
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 69 (3) , 983-990
- https://doi.org/10.1124/mol.105.015479
Abstract
We investigated the role of soluble guanylate cyclase in lipopolysaccharide-induced hyporesponsiveness to phenylephrine. The effects of phenylephrine on the blood pressure of female Wistar rats were evaluated at 2, 8, and 24 h after lipopolysaccharide injection (12.5 mg/kg i.p.). Vasoconstrictive responses to phenylephrine were reduced 40 to 50% in all time periods. Methylene blue, a soluble guanylate cyclase inhibitor (15 μmol/kg i.v.) restored the reactivity to phenylephrine in animals injected with lipopolysaccharide 2 and 24 h earlier. However, it failed to do so in animals injected with lipopolysaccharide 8 h earlier. Incubation with sodium nitroprusside (SNP) increased lung and aorta cGMP levels in control animals and in tissues of rats treated with lipopolysaccharide 24 h earlier. However, SNP failed to increase tissue cGMP in rats injected 8 h earlier. Lipopolysaccharide reduced the vasodilatory response to NO donors 8 h after injection. This effect and the decreased lung cGMP accumulation in response to SNP were reversed by an NO synthase blocker. Guanylate cyclase protein levels were lower than controls in lungs harvested from rats injected 8 h earlier and were back to normal values in lungs of rats injected 24 h earlier with lipopolysaccharide. Thus, data indicate that there is a temporal window of 8 h after lipopolysaccharide injection in which soluble guanylate cyclase is not functional and that this loss of function is NO-dependent. Thus, the putative use of soluble guanylate cyclase inhibitors in the treatment of endotoxemia may be beneficial mainly at early stages of this condition.This publication has 40 references indexed in Scilit:
- Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*Critical Care Medicine, 2004
- Differential Involvement of Guanylate Cyclase and Potassium Channels in Nitric Oxide-Induced Hyporesponsiveness to Phenylephrine in Endotoxemic RatsShock, 2002
- Effects of a novel guanylyl cyclase inhibitor on the vascular actions of nitric oxide and peroxynitrite in immunostimulated smooth muscle cells and in endotoxic shockCritical Care Medicine, 1999
- Nitric oxide in septic shockPublished by Elsevier ,1999
- Treatment of SepsisDrugs, 1999
- Escherichia coliLipopolysaccharide Downregulates Soluble Guanylate Cyclase in Pulmonary Artery Smooth MuscleJournal of Surgical Research, 1998
- Effects of Methylene Blue on Blood Pressure and Reactivity to Norepinephrine in Endotoxemic RatsJournal of Cardiovascular Pharmacology, 1993
- N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin.The Journal of Experimental Medicine, 1992
- Cytoprotective function of nitric oxide: Inactivation of superoxide radicals produced by human leukocytesBiochemical and Biophysical Research Communications, 1991
- Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesisBiochemical and Biophysical Research Communications, 1990